Affibody’s vision is to be a leading player in the emerging field of personalized medicine within oncology, and a preferred partner and provider of high-quality biotechnology products. Affibody uses innovative protein-engineering technologies for the development of affinity ligands. Based on its proprietary technology platform, Affibody is developing a unique oncology pipeline, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics.
- Sector: Healthcare
- Status: Private
- Geographic Market: Europe
- Investment Year: 2000
- Board Representation: Jakob Lindberg
Visit the company’s website.
